- Home
- DXCM vs WAT Comparison
DXCM vs WAT Comparison
Compare DXCM & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXCM
- WAT
- Stock Information
- Founded
- DXCM 1999
- WAT 1958
- Country
- DXCM United States
- WAT United States
- Employees
- DXCM N/A
- WAT N/A
- Industry
- DXCM Medical/Dental Instruments
- WAT Biotechnology: Laboratory Analytical Instruments
- Sector
- DXCM Health Care
- WAT Industrials
- Exchange
- DXCM Nasdaq
- WAT Nasdaq
- Market Cap
- DXCM 31.7B
- WAT 17.8B
- IPO Year
- DXCM 2005
- WAT 1995
- Fundamental
- Price
- DXCM $75.78
- WAT $306.63
- Analyst Decision
- DXCM Strong Buy
- WAT Hold
- Analyst Count
- DXCM 19
- WAT 14
- Target Price
- DXCM $99.89
- WAT $374.07
- AVG Volume (30 Days)
- DXCM 4.7M
- WAT 603.2K
- Earning Date
- DXCM 10-23-2025
- WAT 10-31-2025
- Dividend Yield
- DXCM N/A
- WAT N/A
- EPS Growth
- DXCM N/A
- WAT 10.77
- EPS
- DXCM 1.43
- WAT 11.09
- Revenue
- DXCM $4,300,800,000.00
- WAT $3,046,056,000.00
- Revenue This Year
- DXCM $17.03
- WAT $7.15
- Revenue Next Year
- DXCM $15.59
- WAT $6.34
- P/E Ratio
- DXCM $53.04
- WAT $27.68
- Revenue Growth
- DXCM 9.30
- WAT 5.89
- 52 Week Low
- DXCM $57.52
- WAT $275.05
- 52 Week High
- DXCM $93.25
- WAT $423.56
- Technical
- Relative Strength Index (RSI)
- DXCM 42.30
- WAT 55.20
- Support Level
- DXCM $75.39
- WAT $294.96
- Resistance Level
- DXCM $77.84
- WAT $311.44
- Average True Range (ATR)
- DXCM 2.51
- WAT 9.19
- MACD
- DXCM -0.00
- WAT 1.02
- Stochastic Oscillator
- DXCM 40.45
- WAT 80.99
About DXCM DexCom Inc.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
About WAT Waters Corporation
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.